Condition: Acromegaly · Sponsor: Camurus AB
The purpose of this study is to collect long-term (up to two years) safety and effectiveness of octreotide subcutaneous depot in patients with acromegaly in the real-world setting.
This description comes directly from the study's public registry record.
Camurus AB · +46 46 286 57 30 · medicalinfo@camurus.com
Always discuss trial participation with your own doctor first.
| Universitaetsklinikum Aachen | Aachen, Germany | Not Yet Recruiting |
| Universitaetsklinikum Leipzig | Leipzig, Germany | Recruiting |
| Fachpraxis für Innere Medizin, Endokrinologie und Diabetologie | Magdeburg, Germany | Not Yet Recruiting |
| Medicover Neuroendokrinologie MVZ | München, Germany | Not Yet Recruiting |
| Universitätsklinikum Würzburg | Würzburg, Germany | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07583563